Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation-Reference-Cited by-同舟云学术

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

Published:2017-03-28 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Liu David S.,Duong Cuong P.,Haupt Sue,Montgomery Karen G.,House Colin M.,Azar Walid J.,Pearson Helen B.,Fisher Oliver M.,Read Matthew,Guerra Glen R.^ORCID,Haupt Ygal,Cullinane Carleen,Wiman Klas G.,Abrahmsen Lars,Phillips Wayne A.^ORCID,Clemons Nicholas J.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms14844.pdf

Reference45 articles.

1. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat. Cell Biol. 15, 2–8 (2013).

2. Bykov, V. J. & Wiman, K. G. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 588, 2622–2627 (2014).

3. Liu, D. S. et al. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut 64, 1506–1516 (2015).

4. Mohell, N. et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 6, e1794 (2015).

5. Peng, X. et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 4, e881 (2013).

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrimidine Triones as Potential Activators of p53 Mutants;Biomolecules;2024-08-08

2. Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer;Translational Oncology;2024-08

3. Targeting apoptotic pathways for cancer therapy;Journal of Clinical Investigation;2024-07-15

4. Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy;International Journal of Molecular Sciences;2024-07-09

5. Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway;Biomedicine & Pharmacotherapy;2024-07